Specialty	Internal Medicine
Subspecialty	Hematology - Internal Medicine
Clinical Interests	Coagulation Disorders
	Stem Cell Transplantation
Languages	English
Gender	Male
E-mail	christopher.walsh@mssm.edu
Education and Training	MD, Tulane University
	Ph.D, Bowman Gray School of Medicine
	A.B., Rutgers College
	Internship, Internal Medicine, North Carolina Memorial Hospital
	Residency, Internal Medicine, North Carolina Memorial Hospital
	Residency, Internal Medicine, National Institutes of Health
	Fellowship, Hematology, National Institutes of Health

Education and Training	MD, Tulane University
	Ph.D, Bowman Gray School of Medicine
	A.B., Rutgers College
	Internship, Internal Medicine, North Carolina Memorial Hospital
	Residency, Internal Medicine, North Carolina Memorial Hospital
	Residency, Internal Medicine, National Institutes of Health
	Fellowship, Hematology, National Institutes of Health
Board Certification	Internal Medicine
	Hematology - Internal Medicine

Specialty	Internal Medicine
Subspecialty	Hematology - Internal Medicine
Clinical Interests	Coagulation Disorders
	Stem Cell Transplantation
Languages	English
Board Certification	Internal Medicine
	Hematology - Internal Medicine

Research
Dr. Walsh directs the Hemophilia Program in the Division of Hematology and Medical Oncology at Mount Sinai School of Medicine. His research focuses on gene therapy of blood diseases. Throughout his career he has had a particular interest in Fanconi anemia and his early work in this area culminated in the first clinical trial in which retroviral vectors were used for gene therapy of patients with Fanconi anemia group C. He is also actively developing gene therapies for hemophilia A and B. 

Walsh CE. Fetal gene therapy- a perspective. Gene Ther 1999; 6: 1200-01.

Chao HJ, Walsh CE. Canine FIX antigen in Chapel Hill strain hemophilia B canine. Haemostasis and Thrombosis 1999; 82: 1378.

Walsh CE, Yountz M, Simpson DE. Cellular localization of Fanconi anemia group A protein. Bioch Biophys Res Commun 1999; 259: 594-599.

McMahon LW, Walsh CE, Lambert M. Human alpha spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex. J Biol Chem 1999; 274: 32904-08.

Gush K, Fu KL, Grompe M, Walsh CE. Phenotypic correction of Fanconi anemia group C knockout mice. Blood 2000; 95: 700-704.

Chao HJ, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 2000 Mar; 95(5): 1594-1599.

Chao HJ, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000; 2(6): 619-623.

Yamada K, Olsen JC, Rao K, Walsh CE. Functional correction of Fanconi anemia group C hematopoietic cells using lentiviral vectors. Mol Ther 2001; 3: 485-90.

Chao HJ, Walsh CE. Induction of tolerance to human factor VIII in mice. Blood 2001; 97(10): 3311-2.